JPS57116017A - Antithrombogenetic or anticoagulative agent - Google Patents
Antithrombogenetic or anticoagulative agentInfo
- Publication number
- JPS57116017A JPS57116017A JP56002724A JP272481A JPS57116017A JP S57116017 A JPS57116017 A JP S57116017A JP 56002724 A JP56002724 A JP 56002724A JP 272481 A JP272481 A JP 272481A JP S57116017 A JPS57116017 A JP S57116017A
- Authority
- JP
- Japan
- Prior art keywords
- panax
- ginseng
- antithrombogenetic
- active component
- heparin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
PURPOSE: To provide an orally administrable antithrombogenetic or anticoagulative agent containing ginseng saponin as an active component, useful for the prevention and remedy of thrombotic cerebromalacia, thrombocytopenic purpura, etc., and free from side effects.
CONSTITUTION: The agent contains ginseng saponin extracted from Panax ginseng C.A.MEYER, Panax japonicus C.A.MEYER, Panax quinchiforium LINNE, and/or Panax pseudo-ginseng WALL., as an active component. It may contain heparin or urokinase as a subsidiary active component. Ginseng saponin has stronger antithrombin activity than heparin and can be used not only as an antithrombogenetic agent but also for the prevention of blood coagulation in the extracorporeal circulation (artificial kidney, artificial heart and lung) and during stronge. Since ginseng saponin has no hemolytic activity in contrast with the other saponins, it can be used as an injection. It is also effective by oral administration in contrast with heparin, exhibits no side effect, and is suitable for the long-term administration.
COPYRIGHT: (C)1982,JPO&Japio
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56002724A JPS57116017A (en) | 1981-01-13 | 1981-01-13 | Antithrombogenetic or anticoagulative agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56002724A JPS57116017A (en) | 1981-01-13 | 1981-01-13 | Antithrombogenetic or anticoagulative agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS57116017A true JPS57116017A (en) | 1982-07-19 |
Family
ID=11537252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56002724A Pending JPS57116017A (en) | 1981-01-13 | 1981-01-13 | Antithrombogenetic or anticoagulative agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57116017A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57123121A (en) * | 1981-01-26 | 1982-07-31 | Sunstar Inc | Thrombolytic agent |
JPH01207243A (en) * | 1988-02-12 | 1989-08-21 | Tsumura & Co | Inhibitor of blood platelet aggregation |
US6255296B1 (en) * | 1994-01-11 | 2001-07-03 | Endomatrix, Inc. | Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease |
CN102920836A (en) * | 2012-11-28 | 2013-02-13 | 徐昌万 | Traditional Chinese medicine composite for treating immune thrombocytopenic purpura |
CN107496617A (en) * | 2017-09-30 | 2017-12-22 | 张雷 | A kind of Chinese medicine composition for being used to treat anaphylactoid purpura |
-
1981
- 1981-01-13 JP JP56002724A patent/JPS57116017A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57123121A (en) * | 1981-01-26 | 1982-07-31 | Sunstar Inc | Thrombolytic agent |
JPH01207243A (en) * | 1988-02-12 | 1989-08-21 | Tsumura & Co | Inhibitor of blood platelet aggregation |
US6255296B1 (en) * | 1994-01-11 | 2001-07-03 | Endomatrix, Inc. | Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease |
CN102920836A (en) * | 2012-11-28 | 2013-02-13 | 徐昌万 | Traditional Chinese medicine composite for treating immune thrombocytopenic purpura |
CN107496617A (en) * | 2017-09-30 | 2017-12-22 | 张雷 | A kind of Chinese medicine composition for being used to treat anaphylactoid purpura |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Harenberg | Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide | |
ES8201596A1 (en) | their preparation and use as medicines. | |
JPS57116017A (en) | Antithrombogenetic or anticoagulative agent | |
JPS5795914A (en) | Antithrombin-like drug | |
JPS57134419A (en) | Stable anticoagulant of blood | |
NO954175L (en) | Use of vWF-containing concentrates as combination therapy in antithrombotic and fibrinolytic therapy | |
JPS5692216A (en) | Peripheral circulation improver containing crude drug | |
JPS57163315A (en) | Preventing agent and remedy for thrombosis | |
JPS56138110A (en) | Suppository containing citric acid or salt thereof | |
JPS55122724A (en) | Antidiabetic agent | |
JPS574922A (en) | Agent for lowering ammonia in blood | |
JPS57128635A (en) | Pharmaceutical preparation of gamma-globulin for venoclysis | |
Porush et al. | Urinary concentrating operation in caval dogs | |
IKUSHIMA et al. | INDICATION OF OPEN TREATMENT FOR TUBERCULOUS EMPYEMA THORACIS | |
JPS55122721A (en) | Antidiabetic agent | |
JPS56138112A (en) | Suppository containing ascorbic acid or sodium ascorbate | |
JPS56125305A (en) | Creamy or milky lotion cosmetic | |
Jing | Dynamic changes of platelet aggregation and serum fibrin derived products after smoke inhalation injury in rabbits | |
JPS5779879A (en) | Safety cabinet | |
Sorsby | Infections of the eye | |
JPS5738724A (en) | Blood sugar level lowering agent | |
Ames | Oxazepam and carbamazepine for alcohol withdrawal | |
Abildgaard et al. | Does the “post-heparin effect” explain the discrepancy between antithrombotic and anticoagulant effects of LMW and standard heparins? | |
JPS57145817A (en) | Remedy for peptic ulcer | |
Hafner et al. | Use of thrombin-antithrombin III complex in controlling low molecular weight heparin treatment during acute dialyses |